VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.45%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$3.44M
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$670K |
| 2 |
Zai Lab
ZLAB
|
$520K |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$422K |
| 4 |
DRD
DRDGold
DRD
|
$405K |
| 5 |
Stellus Capital Investment Corp
SCM
|
$402K |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
$1.28M |
| 2 |
Prothena Corp
PRTA
|
$971K |
| 3 |
BioNTech
BNTX
|
$787K |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
$647K |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$645K |
Sector Composition
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Atara Biotherapeutics
ATRA
$90.7M
| $237K | 0.1% |
610
+99
| +19% | +$38.5K |
|
227
BioAtla
BCAB
$31.5M
| $237K | 0.1% |
+5,603
| New | +$237K |
|
228
Codexis
CDXS
$218M
| $235K | 0.1% |
10,385
-5,564
| -35% | -$126K |
|
229
ESSA Pharma
EPIX
$11M
| $235K | 0.1% |
+8,233
| New | +$235K |
|
230
Krystal Biotech
KRYS
$4.35B
| $235K | 0.1% |
3,455
-1,696
| -33% | -$115K |
|
231
Denali Therapeutics
DNLI
$2.26B
| $234K | 0.1% |
2,980
-664
| -18% | -$52.1K |
|
|
AMRS
232
DELISTED
Amyris Inc.
AMRS
| $234K | 0.1% |
14,284
-77,973
| -85% | -$1.28M |
|
|
RXDX
233
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $234K | 0.1% |
+9,519
| New | +$234K |
|
|
MYOV
234
DELISTED
Myovant Sciences Ltd.
MYOV
| $234K | 0.1% |
10,270
-2,187
| -18% | -$49.8K |
|
235
AnaptysBio
ANAB
$613M
| $233K | 0.1% |
8,987
-3,489
| -28% | -$90.5K |
|
236
Inovio Pharmaceuticals
INO
$148M
| $233K | 0.1% |
2,092
-312
| -13% | -$34.8K |
|
237
Akebia Therapeutics
AKBA
$785M
| $232K | 0.1% |
61,284
-33,148
| -35% | -$125K |
|
238
Regenxbio
RGNX
$490M
| $232K | 0.1% |
5,962
-1,516
| -20% | -$59K |
|
239
Vir Biotechnology
VIR
$732M
| $232K | 0.1% |
4,912
-4,302
| -47% | -$203K |
|
240
FibroGen
FGEN
$48.9M
| $231K | 0.1% |
347
+74
| +27% | +$49.3K |
|
241
Allogene Therapeutics
ALLO
$255M
| $230K | 0.09% |
8,817
-1,904
| -18% | -$49.7K |
|
242
Ardelyx
ARDX
$1.57B
| $229K | 0.09% |
30,187
-13,462
| -31% | -$102K |
|
243
Novavax
NVAX
$1.28B
| $229K | 0.09% |
1,077
-1,231
| -53% | -$262K |
|
|
SWTX
244
DELISTED
SpringWorks Therapeutics
SWTX
| $229K | 0.09% |
2,774
-1,232
| -31% | -$102K |
|
|
ALBO
245
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $229K | 0.09% |
6,523
-803
| -11% | -$28.2K |
|
|
SRNE
246
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $229K | 0.09% |
23,646
-16,454
| -41% | -$159K |
|
|
FMTX
247
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $229K | 0.09% |
9,220
+2,944
| +47% | +$73.1K |
|
|
BCYC
248
Bicycle Therapeutics
BCYC
$496M
| $228K | 0.09% |
+7,509
| New | +$228K |
|
249
MeiraGTx Holdings
MGTX
$619M
| $228K | 0.09% |
14,736
-8,443
| -36% | -$131K |
|
250
Sangamo Therapeutics
SGMO
$165M
| $228K | 0.09% |
19,037
-3,913
| -17% | -$46.9K |
|